American Well (NYSE:AMWL – Get Free Report) and HeartBeam (NASDAQ:BEAT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.
Insider and Institutional Ownership
56.1% of American Well shares are owned by institutional investors. Comparatively, 7.8% of HeartBeam shares are owned by institutional investors. 12.8% of American Well shares are owned by company insiders. Comparatively, 18.0% of HeartBeam shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares American Well and HeartBeam”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| American Well | $249.32 million | 0.51 | -$95.70 million | ($5.42) | -1.43 |
| HeartBeam | N/A | N/A | -$21.01 million | ($0.56) | -1.71 |
HeartBeam has lower revenue, but higher earnings than American Well. HeartBeam is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and target prices for American Well and HeartBeam, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| American Well | 1 | 4 | 1 | 0 | 2.00 |
| HeartBeam | 1 | 2 | 4 | 1 | 2.63 |
American Well presently has a consensus target price of $7.30, indicating a potential downside of 5.89%. HeartBeam has a consensus target price of $4.83, indicating a potential upside of 403.84%. Given HeartBeam’s stronger consensus rating and higher possible upside, analysts plainly believe HeartBeam is more favorable than American Well.
Profitability
This table compares American Well and HeartBeam’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| American Well | -37.02% | -32.11% | -24.12% |
| HeartBeam | N/A | -1,034.04% | -434.40% |
Risk and Volatility
American Well has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, HeartBeam has a beta of -0.86, meaning that its stock price is 186% less volatile than the S&P 500.
Summary
HeartBeam beats American Well on 8 of the 14 factors compared between the two stocks.
About American Well
American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members. It provides Carepoint devices comprising carts, peripherals, tablets, and TVs, which serve as digital access points in clinical settings. In addition, the company offers Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, acute psychiatry, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.
About HeartBeam
BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.
Receive News & Ratings for American Well Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Well and related companies with MarketBeat.com's FREE daily email newsletter.
